Q1 2024 Geron Corp Earnings Call Transcript
Key Points
- FDA's Oncology Drug Advisory Committee voted favorably on imetelstat's clinical benefit for lower-risk MDS, indicating strong regulatory support.
- Imetelstat is positioned to address significant unmet needs in transfusion-dependent lower-risk MDS, especially in high transfusion burden and RS negative patients.
- Geron Corp is in the final stages of commercial readiness, with a fully trained sales force ready for deployment upon potential approval.
- The company has a strong financial position with approximately $465 million on the balance sheet, supporting the planned U.S. commercial launch.
- Positive feedback from the lower-risk MDS community during the public forum, highlighting the need for new treatments and the potential impact of imetelstat.
- The timeline for the Phase 3 IMpact MF trial has been extended by half a year, with interim analysis now expected in early 2026 and final analysis in early 2027.
- Lower than anticipated enrollment and death rates in the IMpact MF trial, which could affect the study's timeline and outcomes.
- Increased operating expenses, with Q1 2024 expenses rising to $56.4 million from $40.1 million in the same period in 2023, reflecting higher costs associated with commercial preparations and increased headcount.
- Potential challenges in updating NCCN guidelines post-approval, which are critical for influencing clinical and payer pathways.
- Uncertainties around the final FDA approval and labeling discussions, which are crucial for the commercial launch and market acceptance of imetelstat.
Thank you for standing by. My name is Jill, and I will be your conference operator today. At this time, I would like to welcome everyone to the Geron Q1 2024 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one. Again, I would now like to turn the conference over to Aron Feingold, you may begin.
Good morning, everyone. Welcome to the Geron Corporation First Quarter 2024 earnings conference call and Aron Feingold Geron's, Vice President of Investor Relations and Corporate Communications.
I'm joined today by several members of Darren's management team, Dr. John Scarlett, Chairman and Chief Executive Officer, Neil Cooper, Executive Vice President of Corporate Strategy and Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
